CSIMarket Company Name, Ticker, Suppliers, else..
 
Maxcyte inc   (MXCT)
Other Ticker:  
 
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $3.6700 $-0.21 -5.412%
Day's High: $3.91 Week Perf: 1.38 %
Day's Low: $ 3.66 30 Day Perf: -7.32 %
Volume (M): 292 52 Wk High: $ 5.55
Volume (M$): $ 1,072 52 Wk Avg: $4.29
Open: $3.88 52 Wk Low: $2.80



 Market Capitalization (Millions $) 384
 Shares Outstanding (Millions) 105
 Employees -
 Revenues (TTM) (Millions $) 45
 Net Income (TTM) (Millions $) -35
 Cash Flow (TTM) (Millions $) -17
 Capital Exp. (TTM) (Millions $) 3

Maxcyte Inc
Maxcyte Inc. is a biotechnology company that specializes in cell engineering and flow electroporation technology. The company is focused on developing innovative solutions for drug discovery, cell and gene therapy, and biomanufacturing. Maxcyte's proprietary technology allows for high levels of transfection efficiency and cell engineering, making it an attractive option for researchers and pharmaceutical companies looking to develop new therapies and improve biomanufacturing processes. The company also offers contract development and manufacturing services, providing support to clients in the development and production of cell-based therapies. Overall, Maxcyte Inc. plays a significant role in advancing the field of cell engineering and facilitating the development of novel therapies.


   Company Address: 9713 Key West Avenue Rockville 20850 MD
   Company Phone Number: 944-1700   Stock Exchange / Ticker: NASDAQ MXCT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Contract

MaxCyte and Kamau Therapeutics Join Forces to Uphold Genetic Disease Treatment with Cutting-Edge Ce...

Published Mon, Sep 16 2024 6:00 AM UTC

In an ambitious stride toward transforming the landscape of genetic disease treatment, MaxCyte Inc., a global leader in cell engineering and therapeutic research, has entered into a strategic platform license agreement with Kamau Therapeutics. This collaboration aims to harness MaxCyte?s sophisticated Flow Electroporation technology and ExPERT platform to bolster Kamau's pio...
Licensing Agreement

' MaxCyte Expands Reach with Strategic Partnerships to Drive Cell Therapy Innovation and Oncological Breakthroughs

Published Wed, May 22 2024 12:05 PM UTC

In a series of transformative agreements, MaxCyte, a pioneering force in cell engineering and electroporation technology, has inked strategic platform licenses with three distinguished biotech companies: Legend Biotech, Wugen, and Imugene. These alliances underscore MaxCyte's pivotal role in advancing cell therapy innovations and scaling clinical and commercial manufacturing...
Maxcyte Inc

MaxCyte Inc. Reports $-0.09 per Share Deficit in First Quarter of 2024 Earnings Season



MaxCyte Inc., a prominent cell-engineering focused company, has recently reported its financial results for the first quarter of 2024. Despite posting a loss of $-0.09 per share, the company witnessed a significant revenue surge of 32.248% to $11.34 million compared to the corresponding quarter a year ago. This growth rate outpaced its peers in the Medical Laboratories sector. Moreover, MaxCyte Inc. recently entered into a strategic partnership with Be Biopharma to advance the development and production of Engineered B Cell Medicines (BCMs), which is expected to impact the company's future results.
Financial Performance:
In the first quarter of 2024, MaxCyte Inc. reported a net deficit of $-9.526 million, an improvement from the deficit of $-10.882 million during the same quarter the previous year. Although the company experienced a decrease in revenue compared to the prior quarter, where it recorded $15.66 million in revenue, the significant surge in revenue compared to the corresponding quarter a year ago is noteworthy.
Licensing Agreement

Advancing Therapies of Tomorrow: MaxCyte and Be Biopharma Join Forces in Engineered B Cell Medicines

Published Tue, Apr 2 2024 12:05 PM UTC

MaxCyte Partners with Be Biopharma to Advance Engineered B Cell MedicinesMaxCyte, a leading biotechnology company, has recently announced a strategic platform license agreement with Be Biopharma, a pioneering player in the field of Engineered B Cell Medicines (BCMs). This collaboration aims to propel the development and production of BCMs by leveraging MaxCyte's cutting-edge...
Maxcyte Inc

Maxcyte Inc. Sees Revenue Surge, But Fails to Reach Profitability Goals in Q4 2023

Maxcyte Inc, a leading cell-engineering focused company, recently announced its fourth quarter and full year financial results for 2023. The company reported a surge in revenue by 26.087% to $15.66 million from the same reporting period a year before. However, it also experienced diminishing returns with a net shortfall of $-0.05 per share.
Despite the positive revenue growth, Maxcyte Inc's shares have gone down by -15.63% in the past 5 trading days and -14.35% from a year ago. Currently, the company's shares are trading on the NASDAQ by -8.4% below its 52 week average.






Maxcyte Inc's Segments
Product sales    45.41 % of total Revenue
Other    2.2 % of total Revenue

  Maxcyte Inc Outlook

On March 12 2024 the Maxcyte Inc provided following guidance

MaxCyte Inc, a prominent company specializing in cell-engineering technologies, recently disclosed its financial results for the fourth quarter and full year ending on December 31, 2023. The company, listed on NASDAQ as MXCT and on the London Stock Exchange as MXCT, reported positive financial performance for the period.

The company reconfirmed its projected guidance for the year 2024, emphasizing its commitment to driving advancements in the discovery, development, and commercialization of next-generation cell therapeutics and innovative bioprocessing applications.

The solid financial results and reiterated guidance demonstrate MaxCyte's success in leveraging its enabling platform technologies...





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com